Safety concerns and risk management of multiple sclerosis therapies

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

(2015) Luisa Klotz et al.   BMC Neurology

Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis

(2015) Aaron E. Miller   CLINICAL THERAPEUTICS

Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis

(2015) Adnan M. Subei et al.   CNS DRUGS

Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis

(2015) Athina Papadopoulou et al.   Expert Opinion On Drug Safety

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2015) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide

(2014) Emanuela Colombo et al.   ANNALS OF NEUROLOGY

New management algorithms in multiple sclerosis

(2014) Per Soelberg Sorensen   CURRENT OPINION IN NEUROLOGY

Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis

(2014) Melanie D Ward et al.   Expert Opinion On Drug Safety

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

(2014) Per Soelberg Sorensen et al.   JOURNAL OF NEUROLOGY

Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis

(2014) A. Gueguen et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

(2014) O. Tuohy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

(2014) Thomas P Leist et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Christian Confavreux et al.   LANCET NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis

(2014) Hans-Peter Hartung et al.   Multiple Sclerosis Journal

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

(2014) G. Karlsson et al.   NEUROLOGY

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab

(2014) Marinella Clerico et al.   JAMA Neurology

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

(2014) John P. DiMarco et al.   Multiple Sclerosis and Related Disorders

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

(2014) Ludwig Kappos et al.   Multiple Sclerosis and Related Disorders

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis

(2013) L. Azzopardi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

(2013) Tomas Olsson et al.   Multiple Sclerosis Journal

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

(2013) N. Schwab et al.   NEUROLOGY

BG-12 in Multiple Sclerosis

(2013) Robert Fox et al.   SEMINARS IN NEUROLOGY

Update on PML and PML-IRIS Occurring in Multiple Sclerosis Patients Treated With Natalizumab

(2012) B.K. Kleinschmidt-DeMasters et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

(2012) Christian Confavreux et al.   Multiple Sclerosis Journal

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

(2012) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Severe relapses under fingolimod treatment prescribed after natalizumab

(2012) D. Centonze et al.   NEUROLOGY

Lethal multiple sclerosis relapse after natalizumab withdrawal

(2012) V. Rigau et al.   NEUROLOGY

Fingolimod-associated macular edema: Incidence, detection, and management

(2012) N. Jain et al.   NEUROLOGY

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

(2011) Jeffrey A. Cohen et al.   ANNALS OF NEUROLOGY

A Benign Form of Neuromyelitis Optica

(2011) Nicolas Collongues   ARCHIVES OF NEUROLOGY

Immune mechanisms of new therapeutic strategies in MS — Teriflunomide

(2011) Malte C. Claussen et al.   CLINICAL IMMUNOLOGY

Principles of a new treatment algorithm in multiple sclerosis

(2011) Hans-Peter Hartung et al.   Expert Review of Neurotherapeutics

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

(2011) Giancarlo Comi et al.   LANCET NEUROLOGY

Intrathecal effects of daclizumab treatment of multiple sclerosis

(2011) B. Bielekova et al.   NEUROLOGY

Immune reconstitution inflammatory syndrome in natalizumab-associated PML

(2011) I. L. Tan et al.   NEUROLOGY

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

(2011) V. Martinelli et al.   NEUROLOGY

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

(2011) M. Mehling et al.   NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

(2010) Richard A. Rudick et al.   ANNALS OF NEUROLOGY

Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple Sclerosis

(2010) Alexandra Schröder et al.   ARCHIVES OF NEUROLOGY

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

(2010) Chris H Polman et al.   LANCET NEUROLOGY

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2010) J. J. Marriott et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD20-Targeted Therapy: The Next Generation of Antibodies

(2010) Tom van Meerten et al.   SEMINARS IN HEMATOLOGY

Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

(2009) Eamonn S. Molloy et al.   ARTHRITIS AND RHEUMATISM

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

(2009) R Ellis et al.   Multiple Sclerosis Journal

Mitoxantrone: benefits and risks in multiple sclerosis patients

(2009) V. Martinelli et al.   NEUROLOGICAL SCIENCES

Mitoxantrone and cytotoxic drugs' mechanisms of action

(2009) T. Vollmer et al.   NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Gene expression analysis of interferon-β treatment in multiple sclerosis

(2008) F Sellebjerg et al.   Multiple Sclerosis Journal

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

(2008) O. Stuve et al.   NEUROLOGY